Holen Sie sich die Stockscreener-App
2.12
6.25%
0.12
Schlusskurs vom Vortag:
$2.00
Offen:
$2.01
24-Stunden-Volumen:
1.43M
Relative Volume:
0.87
Marktkapitalisierung:
$385.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-236.93M
KGV:
-1.4614
EPS:
-1.4507
Netto-Cashflow:
$-206.44M
1W Leistung:
+10.10%
1M Leistung:
-29.64%
6M Leistung:
+12.43%
1J Leistung:
+188.53%
1-Tages-Spanne:
$1.97
$2.15
1-Wochen-Bereich:
$1.89
$2.15
52-Wochen-Spanne:
$0.611
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.12 | 364.08M | 0 | -236.93M | -206.44M | -1.4507 |
VRTX
Vertex Pharmaceuticals Inc
|
433.56 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.84 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.14 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.59 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.86 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat
ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake - Stock Titan
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - globenewswire.com
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Guggenheim - The Globe and Mail
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead - tipranks.com
Loss Report: Will Neumora Therapeutics Inc benefit from geopolitical trendsQuarterly Market Summary & Trade Opportunity Analysis - baoquankhu1.vn
Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $6 to $18 - Moomoo
Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access - tipranks.com
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% By Investing.com - Investing.com India
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
Guggenheim reiterates Neumora stock rating on pipeline progress By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Neumora Therapeutic (NMRA.US) will release its earnings report before the market opens on March 30. - Moomoo
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics 2025 Financial Update - AlphaStreet
Neumora Therapeutics Reports Strong 2025 Financials and Clinical Pipeline Progress Including NMRA-511 Alzheimer’s Agitation Data and KOASTAL-2/3 Enrollment 123 - Minichart
Stifel reiterates Neumora Therapeutics stock Hold rating at $3 By Investing.com - ca.investing.com
Neumora Therapeutics Sees Unusually Large Options Volume (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Neumora 2025 10-K Report: Precision Neuroscience, Intellectual Property, and Business Overview - Minichart
Neumora Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Neumora Therapeutics beats Q4 2025 EPS forecast, stock dips - investing.com
Neumora Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% - au.investing.com
Neumora Therapeutics, Inc. (NMRA) Q4 FY2025 earnings call transcript - Yahoo Finance
Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Neumora (NASDAQ: NMRA) maps key 2026–27 milestones for depression, Alzheimer’s and obesity drugs - Stock Titan
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Neumora (NMRA) posts 2025 loss, advances CNS pipeline with key 2026–27 milestones - Stock Titan
With 400-plus in each trial, Neumora heads for a Q2 drug readout - Stock Titan
NMRA PE Ratio & Valuation, Is NMRA Overvalued - Intellectia AI
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Neumora Therapeutics (NMRA) price target decreased by 16.15% to 7.82 - MSN
Neumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most - Benzinga
Neumora Therapeutics Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Sahm
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neumora Therapeutics Inc-Aktie (NMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):